This drug can double survival time for pancreatic cancer patients

A new clinical trial has shown that the drug daraxonrasib can nearly double survival time for patients with advanced pancreatic cancer. The study, involving 500 patients, found those taking the daily pill lived an average of 13.2 months, compared to 6.6–6.7 months for patients receiving standard chemotherapy. The results were presented at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago. Daraxonrasib works by targeting the Kras protein, which is overactive in over 90% of pancreatic ductal adenocarcinoma (mPDAC) cases. The drug binds to molecules to deactivate Kras, a key driver of the cancer’s progression. Experts described the findings as a breakthrough, with Dr. Rachna Shroff, Chief of Oncology at the University of Arizona Cancer Center, calling them 'landscape-changing.' The drug’s potential impact was widely praised by advocacy groups. Paula Hanford, CEO of UK-based Pancreatic Cancer Action, called the results 'one of the biggest breakthroughs' in treatment she has witnessed, offering hope for patients and families. Anna Jewell from Pancreatic Cancer UK echoed these sentiments, emphasizing the drug’s potential to improve survival rates for those with advanced disease. Pancreatic cancer remains one of the deadliest forms of cancer, often diagnosed late. The trial’s results suggest daraxonrasib could revolutionize treatment options, providing a much-needed advancement in combating the disease. Further research and regulatory approval will be necessary before the drug becomes widely available.